A wide range of proteins are attached to the external face of the plasma membrane of eukaryotic cells via a glycosyl-phosphatidyl-inositol (GPI) anchor (1,2). The function of many GPIanchored proteins is to transport small molecules and ions across the plasma membrane by the process of potocytosis (3). Synthetic GPI-anchored versions of some type I integral membrane proteins and secreted proteins have been generated by replacement of their TM and cytoplasmic domains with a GPI-attachment signal (1, (4) (5) (6) (7) (8) . One of these GPI-proteins has been used as a targeting molecule for liposomes (9); GPI-proteins could also be used for. exploring the function of the transmembrane domain of type I membrane proteins.
A wide range of proteins are attached to the external face of the plasma membrane of eukaryotic cells via a glycosyl-phosphatidyl-inositol (GPI) anchor (1, 2) . The function of many GPIanchored proteins is to transport small molecules and ions across the plasma membrane by the process of potocytosis (3) . Synthetic GPI-anchored versions of some type I integral membrane proteins and secreted proteins have been generated by replacement of their TM and cytoplasmic domains with a GPI-attachment signal (1, (4) (5) (6) (7) (8) . One of these GPI-proteins has been used as a targeting molecule for liposomes (9) ; GPI-proteins could also be used for. exploring the function of the transmembrane domain of type I membrane proteins.
A simple method for the construction of GPI-anchored proteins is not available. We describe here the construction of a GPIanchored version of FcyRI, the high affinity receptor for IgG (10) , by using the signal for GPI-anchor attachment from the cell surface receptor molecule, LFA-3 (11) using the eukaryotic expression vector CDM. We then show how this clone can be used in a simple one step cloning procedure to transform other type I membrane proteins into GPI-anchored proteins. This method should work equally well with secreted proteins.
To generate a GPI-anchored version of FcyRI, two clones were constructed. The first chimeric receptor (FC7RI-LFA3/28) comprises the complete extracellular region of FcyRI fused to the carboxy-terminal 28 amino acids of LFA-3 via a BamHI linker ( Fig. 1 ) and includes only part of the predicted signal for GPIanchor attachment (1, 11) . The second chimeric receptor (FcyRI-LFA3/31) has an additional three amino acids, which includes the complete signal for GPI-anchor attachment.
Plasmid DNA was transiently transfected into COS cells using the DEAE-dextran method (10) . Both FcyRI-LFA3/28c and FcyRI-LFA3/31 were expressed at similar levels to the wild type FcyRI ( Fig. 2A-C) . To determine whether these proteins were GPI-linked, cells were treated with phosphatidylinositol-specific phospholipase C (PIPLC), an enzyme which hydrolyses GPIanchors and thereby liberates the protein from the cell surface; this loss can be detected by immunofluorescence and FACS analysis (1) (2) (3) . Figure 2F shows that only FcyRl-LFA3/31 (renamed FcyRI-GPI) is GPI-linked, demonstrating that the carboxy-terminal 31 amino acids of LFA-3 are necessary and sufficient for GPI-anchor formation.
The FcyRI-GPI clone was used for the construction of a GPIanchored version of CD2. The extracellular domain of CD2 (12) was amplified by PCR using a forward primer (5'-TTCCTTC-ACAAAGATCCTCT-3') which hybridises to the CDM vector, and a reverse primer (5'-GATGGGATCCATGTCCAGACC-3') that contains an internal BamHI site. The PCR product, which gains a HindJQ site from the vector and the BamHI site from the reverse, primer, was subcloned between the unique HindJH and BamHI sites of the FcyRI-GPI clone. The resulting clone (CD2-GPI) was transiently transfected in COS cells. CD2-GPI (Fig. 2H ) was expressed at similar levels to wild-type CD2 (Fig.  2G) ; only CD2-GPI was liberated by PIPLC treatment (Fig. 2K) .
In summary, we have constructed GPI-linked versions of two type I membrane proteins. The first, FcyRI-GPI, confirms the predicted GPI-anchor signal motif of LFA-3, and serves as a useftil vector for the construction of other GPI-anchored proteins. The second, CD2-GPI, was made from FcyRI-GPI via a simple one-step cloning, procedure (summarised in Figure 3 ) and demonstrates the ease with which further GPI-anchored proteins could be constructed. 
S I I L T T C I P S S O H S R Y A L I TCAATCATTTTGACAACCTGTATCCCAAGCAGCCGTCATTCAAGATATGCACTTATA
CD2-GPI* Figure 1 . Alignment of partial amino acid and nucleotide sequences of wild type and chimeric receptors. Predicted transmembrane domains are double underlined, GPI-anchor signal sequences are shown in bold, BamHI linker sequence is underlined, and convenient restriction sites are also indicated. Clones marked with an asterisk (*) are GPI-anchored. Dots are added for sequence alignment purposes only. Figure 2 . FACS analysis of transiently transfected COS cells to identify GPIanchored clones. FC7RI and FcYRI-chimeras were detected using FITC-labelled IgG. The surface expression of FcyRI (A) and FC7RI-LFA3/28 (B) was not affected by PIPLC treatment (D and E respectively). In contrast, the level of FC7RI-GPI surface expression (C) was reduced to almost background (see I) when treated with PIPLC (F). Surface expression of CD2 and CD2-GPI was detected using a FITC-labelled anti-CD2 monoclonal antibody. CD2 expression (G) is unaffected by PIPLC treatment (J), whereas the surface expression of CD2-GPI (H) is reduced to background levels (see L) following PIPLC treatment (K).
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